ISCATECH   Bedoukian   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Chemtica
Biochemtech
AlphaScents
U-Chemo
BIOHOME
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous AbstractThe effect of intrathecal fentanyl on Cerebral State Index-guided sedation during spinal anaesthesia    Next AbstractThyroid hormone receptor alpha can control action potential duration in mouse ventricular myocytes through the KCNE1 ion channel subunit »

Acta Ophthalmol


Title:Lattice corneal dystrophy, gelsolin type (Meretoja's syndrome)
Author(s):Carrwik, C. Stenevi, U.
Address:Department of Ophthalmology, Sahlgrenska University Hospital, Molndal, Gothenburg, Sweden.
Year:2009 Nov
Journal Title:Acta Ophthalmol
Page Number:813-9
Language:eng
Volume:87
Issue:8
ISSN/ISBN:1755-3768 (Electronic). 1755-375X (Linking)
Abstract:PURPOSE: This paper reviews current knowledge about the pathogenesis, clinical manifestations and treatment of lattice corneal dystrophy, gelsolin type (LCD2, Meretoja's syndrome). METHODS: Material is derived from literature searches, a case study of a Finnish patient living in Sweden, and interviews in Helsinki with Professor Ahti Tarkkanen and Dr Sari Kiuru-Enari, both of whom have extensive first-hand experience in treating patients with the disease. RESULTS: The disease is now reported from several countries in Europe, as well as Japan, the USA and Iran. Treatment is symptomatic and is based on eye lubrication combined with rigorous monitoring of intraocular pressure to reduce corneal haze and postpone the need for keratoplasty. When systemic symptoms occur, the ophthalmologist should consult other specialists. CONCLUSIONS: The disease is probably under-reported and is almost certainly to be found in more countries, including Sweden. Every ophthalmologist should be vigilant and consider this diagnosis when discovering a corneal lattice dystrophy, especially because the disease is an inherited, lifelong chronic condition with systemic symptoms.

 
Back to top
 
Citation: El-Sayed AM 2021. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2021 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 04-03-2021